title: The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network.
abstract: Despite the increased use of intensive immunosuppressive chemo-immunotherapies in patients with lymphoma observed in the last decade, current data on cytomegalovirus (CMV) infection following autologous stem cell transplantation (Auto-SCT) are very limited. To address this peculiar aspect, a retrospective study on a cohort of 128 adult patients consecutively transplanted for lymphoma in three Hematology Institutions was performed with the aim to determine the incidence of and the risk factors for CMV symptomatic infection and/or end-organ disease. Sixteen patients (12.5%) required specific antiviral therapy and 4/16 died (25%); transplant-related mortality (TRM) was significantly influenced by CMV infection (P = 0.005). In univariate analysis, a pre-transplant HBcIgG seropositivity, HBV infection according to clinical-virological definitions, a pre-transplant Rituximab treatment, a diagnosis of B-cell non-Hodgkin lymphoma, and age at transplant were significantly associated with the risk of developing a clinically relevant CMV infection. In multivariate analysis, only a pre-transplant HBcIgG seropositivity (P = 0.008) proved to be an independent predictor of a clinically relevant CMV infection. These results suggest that a pre-transplant HBcIgG seropositivity could be considered as an independent predictor factor of clinically relevant CMV infection after Auto-SCT.
authors.affiliation: Hematology Unit, Campus Bio-Medico University Hospital, Rome, Italy. f.marchesi@unicampus.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Marchesi
authors.forename: Federica
authors.initials: F
authors.lastname: Giannotti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Avvisati
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Petti
authors.forename: Fulvia
authors.initials: F
authors.lastname: Pimpinelli
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Paba
authors.forename: Maria Laura
authors.initials: ML
authors.lastname: Dessanti
authors.forename: Raffaella
authors.initials: R
authors.lastname: Cerretti
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Tirindelli
authors.forename: Alessandra
authors.initials: A
authors.lastname: Picardi
authors.forename: Mariella
authors.initials: M
authors.lastname: D'Andrea
authors.forename: Antonio
authors.initials: A
authors.lastname: Spadea
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Ensoli
authors.forename: Carlo Federico
authors.initials: CF
authors.lastname: Perno
authors.forename: Andrea
authors.initials: A
authors.lastname: Mengarelli
authors.forename: William
authors.initials: W
authors.lastname: Arcese
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006512:Hepatitis B Core Antigens / Q000097:blood* / Q000276:immunology; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries; D012307:Risk Factors; D000069283:Rituximab; D012384:Rome; D014182:Transplantation, Autologous
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D015415:Biomarkers; D006512:Hepatitis B Core Antigens; D000069283:Rituximab